Refractory Hypocalcemia Induced by Denosumab and Nab-Paclitaxel in a Patient With Metastatic Breast Cancer
AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 827-831
DOI: 10.1016/j.aed.2026.02.011 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Mohammed Nabeel Pervez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, England, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background/Objective: Hypocalcemia is a recognized complication of denosumab, yet additive effects from concurrent chemotherapeutic agents are rarely described. We present a case of refractory hypocalcemia due to combined denosumab and nab-paclitaxel in a young woman with metastatic breast cancer. Case Report: A 35-year-old woman with metastatic breast carcinoma and spinal metastases was started on palliative chemotherapy with weekly nab-paclitaxel and denosumab. She had normal renal function and normal baseline calcium and vitamin D levels. Within days of denosumab administration, she developed symptomatic hypocalcemia requiring intravenous calcium replacement. Despite aggressive oral and IV calcium and vitamin D supplementation, her calcium levels repeatedly declined after each cycle of nab-paclitaxel. Other causes of hypocalcemia were excluded. The pattern suggested denosumab as the initial precipitant, with nab-paclitaxel contributing to the persistence and recurrence of hypocalcemia.
Discussion
Denosumab induces hypocalcemia by inhibiting osteoclastic bone resorption, while nab-paclitaxel has been associated with broader electrolyte disturbances, including calcium depletion. In this patient, concurrent exposure likely produced an additive effect, preventing normalization of calcium despite preserved renal function. The case underscores the need for awareness of potential synergistic toxicity when combining agents with similar metabolic adverse effects.
Conclusion
Concurrent use of denosumab and nab-paclitaxel may significantly increase the risk and duration of hypocalcemia. Close biochemical monitoring, early endocrine-oncology multidisciplinary involvement, and timely treatment adjustments are critical to prevent complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, England, United Kingdom.
- Department of Endocrine/Diabetes & General Internal Medicine, Lancaster, Lancashire, United Kingdom.
Zitieren
APA
Pervez, M. N., Ahmad, H., Kashif, M., & Ur Rehman, H. (2026). Refractory Hypocalcemia Induced by Denosumab and Nab-Paclitaxel in a Patient With Metastatic Breast Cancer. AACE Endocrinology and Diabetes, 13(5), 827-831. https://doi.org/10.1016/j.aed.2026.02.011
Vancouver
Pervez MN, Ahmad H, Kashif M, Ur Rehman H. Refractory Hypocalcemia Induced by Denosumab and Nab-Paclitaxel in a Patient With Metastatic Breast Cancer. AACE Endocrinology and Diabetes. 2026;13(5):827-831. doi:10.1016/j.aed.2026.02.011
BibTeX
@article{Pervez2026,
author = {Pervez, Mohammed Nabeel and Ahmad, Hassaan and Kashif, Muhammad and Ur Rehman, Hassan},
title = {Refractory Hypocalcemia Induced by Denosumab and Nab-Paclitaxel in a Patient With Metastatic Breast Cancer},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {5},
pages = {827--831},
doi = {10.1016/j.aed.2026.02.011}
}
EUVIMED